Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish ...

Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.

Novo Nordisk's (NVO) contract Ypsomed to supply the company with injection pens designed to deliver its next-gen obesity ...

The latest health news highlights FDA's approval of BridgeBio's drug for a rare heart condition, cancer features in healthy ...

Now, a partnership between Ypsomed and Sidekick Heath aims to tackle that problem. Ypsomed is a top developer of injection and infusion systems, so knows a lot about the difficulties that patients ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs Ozempic and Wegovy. Novo Nordisk, the manufacturer of both, recently ...

LONDON, Nov 6 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the ...

So on that note, Ypsomed Holding (VTX:YPSN) looks quite promising in regards to its trends of return on capital. If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit ...

Ypsomed Holding AG (VTX:YPSN), is not the largest company out there, but it received a lot of attention from a substantial price movement on the SWX over the last few months, increasing to CHF437 ...

Becton, Dickinson and Company announced a strategic collaboration with Ypsomed, a developer of injection systems, to advance self-injection solutions for high-viscosity biologic drugs.